Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Krystal Biotech, Inc. - Common Stock (NQ:KRYS)

335.19 +7.69 (+2.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 520,339
Open 327.55
Bid (Size) 317.40 (40)
Ask (Size) 335.00 (40)
Prev. Close 327.50
Today's Range 326.01 - 338.58
52wk Range 130.50 - 382.54
Shares Outstanding 22,205,642
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
These 3 Healthcare Stocks Have Crushed the Market This Year. Here's Why There's More Upside Ahead ↗
They are riding strong tailwinds that could lift them higher. 
Via The Motley Fool
Topics Economy
News headline image
Why Tutor Perini Stock Trounced the Market on Tuesday ↗
It's about to join a notable small-cap stock index. 
Via The Motley Fool
Topics Stocks

Performance

YTD
+35.8%
+35.8%
1 Month
-1.5%
-1.5%
3 Month
+25.1%
+25.1%
6 Month
+15.9%
+15.9%
1 Year
+118.7%
+118.7%

More News

Read More
Krystal Biotech (NASDAQ:KRYS) Shows High-Growth Momentum With Perfect Minervini Trend Template Setup ↗
Via Chartmill
News headline image
3 Soaring Stocks That May Have More Upside Ahead ↗
Via The Motley Fool
Krystal Biotech (NASDAQ:KRYS) Combines Perfect Trend Template with High-Growth Momentum ↗
Via Chartmill
Krystal Biotech (NASDAQ:KRYS) Surges After Q1 Beat as VYJUVEK Revenue Hits $116.4M ↗
Via Chartmill
News headline image
3 Biotech Firms With Major Potential Catalysts in the Coming Months ↗
Via MarketBeat
Topics Intellectual Property
News headline image
These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead ↗
Via The Motley Fool
News headline image
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Tech Fund Made a $5.8 Million Bet on an AI Chip Stock Up Nearly 200% Post-IPO ↗
Via The Motley Fool
Topics Artificial Intelligence Initial Public Offering Regulatory Compliance
News headline image
This AI Semiconductor Stock Beat the S&P 500 by 9 Points. A Fund Just Exited Completely ↗
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance Stocks
News headline image
Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug ↗
Via The Motley Fool
News headline image
Krystal (KRYS) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Krystal (KRYS) Q1 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
Is Paymentus Stock a Buy After Palisades Investment Partners Increased Its Stake By $6 Million? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Is Amprius Technologies Stock a Buy After Palisades Investment Partners Initiated a Position Worth $4.8 Million? ↗
Via The Motley Fool
Topics Electric Vehicles Regulatory Compliance
News headline image
Palisades Investment Partners Initiated a Position in SkyWater Technology Stock. What Does This Mean for Investors? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist ↗
Via The Motley Fool
News headline image
Is Vertex Pharmaceuticals' Empire in Trouble? ↗
Via The Motley Fool
News headline image
Could This Under-the-Radar Healthcare Stock Set You Up for Life? ↗
Via The Motley Fool
News headline image
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop ↗
Via The Motley Fool
News headline image
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗
Via The Motley Fool

Frequently Asked Questions

Is Krystal Biotech, Inc. - Common Stock publicly traded?
Yes, Krystal Biotech, Inc. - Common Stock is publicly traded.
What exchange does Krystal Biotech, Inc. - Common Stock trade on?
Krystal Biotech, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Krystal Biotech, Inc. - Common Stock?
The ticker symbol for Krystal Biotech, Inc. - Common Stock is KRYS on the Nasdaq Stock Market
What is the current price of Krystal Biotech, Inc. - Common Stock?
The current price of Krystal Biotech, Inc. - Common Stock is 335.19
When was Krystal Biotech, Inc. - Common Stock last traded?
The last trade of Krystal Biotech, Inc. - Common Stock was at 07/24/26 04:00 PM ET
What is the market capitalization of Krystal Biotech, Inc. - Common Stock?
The market capitalization of Krystal Biotech, Inc. - Common Stock is 7.44B
How many shares of Krystal Biotech, Inc. - Common Stock are outstanding?
Krystal Biotech, Inc. - Common Stock has 7B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.